Daniel Dolan
Keine laufenden Positionen mehr
Profil
Daniel Dolan worked as Vice President of Financial Planning & Analysis at Radius Health, Inc. from 2020 to 2021.
Prior to that, he worked at Shire Plc as Vice President of Finance Global Product Strategy from 2016 to 2017.
Currently, he is the Chief Financial Officer at Nabriva Therapeutics Plc, a position he started in 2021 and will hold until 2023.
Dolan received his undergraduate degree and MBA from Widener University.
Ehemalige bekannte Positionen von Daniel Dolan
| Unternehmen | Position | Ende |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Finanzdirektor/CFO | 30.06.2023 |
| RADIUS HEALTH, INC. | Finanzdirektor/CFO | 15.12.2020 |
| SHIRE | Corporate Officer/Principal | 01.07.2017 |
Ausbildung von Daniel Dolan
| Widener University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
